Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-CD303 in Autoimmune Diseases
NCT03370627Completed
- Sponsor
- CHU de Lille
- Start
- Dec 2017
- Primary completion
- May 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Open-label trial of ch122A2 in systemic lupus erythematosus (SLE), systemic sclerosis (SSc), Sjögren's syndrome and 1 more, sponsored by CHU de Lille. Primary endpoint: Type I Interferon. Started Dec 2017; status: completed.
02
Drugs
ch122A2
03
Conditions
systemic lupus erythematosus (SLE)systemic sclerosis (SSc)Sjögren's syndromeimmune thrombocytopenic purpura (ITP)
Beyond the preview
Go deeper on NCT03370627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03370627.